JosephBlaineBarneyMD

Pulmonology • Birmingham, AL

Critical Care Medicine, Interstitial Lung Diseases, Pleural Disease, Restrictive Lung Disease

Professor, Medicine, University of Alabama School of Medicine

Join to view full profile

Dr. Barney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Barney's full profile

Already have an account?

Office
1717 6th Ave S
Birmingham, AL 35233
Phone+1 800-822-8816

Education & Training

University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2006
University of Alabama Medical CenterResidency, Internal Medicine, 2000 - 2003
Mercer University School of MedicineClass of 2000

Certifications & Licensure

AL State Medical License 2001 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

UAB Pulmonary Ambulatory Medicine Teacher Award UAB, 2023
UAB Patient Experience Excellence Award UAB, 2022
Patient Gold Star Award Birmingham Veterans Administration Medical Center, 2022
Jack Fulmer Teaching Award UAB Division of Pulmonary and Critical Care, 2020
Best Doctors in America 2019-2020
Outstanding Teaching Award University of Alabama at Birmingham Undergraduate Honors Program, 2019
Shakelford Alumni Achievement Award LaGrange College, 2016
Unsung Hero Award University of Alabama Pulmonary Division, 2014
Join now to see all

Clinical Trials

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Start of enrollment: 2019 Jan 29
Completed
Phase 1, Phase 2
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Start of enrollment: 2022 Sep 15
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis Start of enrollment: 2022 Aug 31
Active, not recruiting
Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis Start of enrollment: 2022 Aug 23
Terminated
Phase 2
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Start of enrollment: 2023 Nov 10
Recruiting
Phase 1, Phase 2
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Start of enrollment: 2024 Mar 01
Enrolling by invitation
Phase 2
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis Start of enrollment: 2024 Mar 21
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

51 citations
A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients.
Robert P. Baughman, Joseph Barney, Lanier O'Hare, Elyse E. Lower
Respiratory Medicine. 2016-01-01
63 citations
Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry.
Oksana A. Shlobin, Vasilis Kouranos, Scott D. Barnett, Esam H. Alhamad, Daniel A. Culver
The European Respiratory Journal. 2020-01-01
141 citations
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
Marc A. Judson, Robert P. Baughman, Ulrich Costabel, Marjolein Drent, Kevin F. Gibson
The European Respiratory Journal. 2014-11-01

Professional Memberships

American College of Chest Physicians - ACCP
Fellow